Takeda Withdraws FDA Application For Dengue Vaccine Candidate On Data Disagreement
Portfolio Pulse from Vandana Singh
Takeda Pharmaceutical Co Ltd has withdrawn its FDA application for its dengue vaccine, TAK-003, due to data collection issues. The future of TAK-003 in the U.S. will be reevaluated. The vaccine is already approved in several countries. Sanofi SA's Dengvaxia, the first dengue vaccine, saw reduced usage due to increased risk of severe disease in certain children. TAK-003 was granted priority review by the FDA in November last year.
July 12, 2023 | 12:32 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Sanofi's Dengvaxia, the first dengue vaccine, saw reduced usage due to increased risk of severe disease in certain children. This could potentially open up the market for other dengue vaccines, such as Takeda's TAK-003.
The reduced usage of Sanofi's Dengvaxia due to increased risk of severe disease in certain children could potentially open up the market for other dengue vaccines. This could benefit companies like Takeda, which are developing their own dengue vaccines. However, the impact on Sanofi's stock is likely to be neutral in the short term, as the news is not directly related to the company's current operations.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50
NEGATIVE IMPACT
Takeda's withdrawal of its FDA application for TAK-003 may delay the vaccine's entry into the U.S. market, potentially impacting the company's future revenues.
Takeda's decision to withdraw its FDA application for TAK-003 means that the vaccine's entry into the U.S. market may be delayed. This could impact the company's future revenues, as the U.S. represents a significant market for the vaccine. The withdrawal is due to data collection issues, which could also raise concerns about the vaccine's efficacy.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100